Engrail Therapeutics acquires biopharma company NeuroCycle Therapeutics
Author : Pankaj Singh | Published Date : 2021-02-04
Engrail Therapeutics Inc. has reportedly acquired Neurocycle Therapeutics, a firm that specializes in sub-type selective GABA-A modulation. According to reliable sources, the acquisition will boost Engrail’s portfolio in the GABA-A space and offer a robust platform for commencing clinical trials with various assets in 2021.
For those unaware, Engrail Therapeutics was established in 2019 and specializes in forging a new path to reduce the immense burden of nervous system-affecting diseases. To develop and catalyze a diversified portfolio of innovative medicines, the company brings together biological insights with clinically relevant solutions.
Engrail leverages its scalable transaction model to advance assets with established mechanisms and efficiently transfer them from production to commercialization, by using a robust scientific approach to identify the most promising therapies.
Vikram Sudarshan, Ph.D., President, and CEO at Engrail Therapeutics reportedly stated that their flexible transaction model and science-first approach enables them to acquire the best assets with a low-risk path to the market where considerable patients need still exists.
He further added that GABA-A is an authenticated target and modulators of these receptors have a therapeutic impact across various psychiatric and neurological conditions. Currently, they have several sub-type selective GABA-A modulators with strong profiles and expect development, cited trusted sources.
Dr. Sudarshan also mentioned that they are committed to developing a premier patient-centric neuroscience organization, with a growing pipeline through co-development, licensing, and acquisitions. He went on to express that over the next few years, their aim is to develop a diverse neuroscience therapeutics pipeline, and the acquisition of NeuroCycle represents another significant step on this path.
Jed Hubbs, Ph.D., President and CEO at NeuroCycle Therapeutics reportedly stated that given their focus and experience in the GABA-A room, they believe that Engrail is an ideal company to carry the work NeuroCycle began. They are looking forward to seeing them bring new drugs to patients who require them, he added.
Financials related to the deal have not been disclosed so far.
Source Credit –
About Author
Pankaj Singh . .
Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605
Related News
Bayers new CEO initiates management job cuts to accelerate decision-making
Bayer newly appointed CEO, Bill Anderson, has reportedly unveiled plans to streamline the companys management structure in a bid to expedite decision-making processes. This marks the first step in a broader effort to transform the embattled German company, which has been under pressure from inv... Read More>>
Smurfit Kappa in Merger Talks with WestRock worth $19 Billion
Smurfit Kappa, a prominent player in the packaging industry, is reportedly engaged in merger discussions with its US counterpart, WestRock. This prospective merger has the potential to create a cardboard box-making powerhouse boasting a market value approaching $19 billion (€17.8 billion). Furt... Read More>>
RBC plans job cuts to take on anticipated economic softening
The Royal Bank of Canada is reportedly planning to reduce its workforce by approximately 1,800 jobs as part of cost-cutting measures, on account of the anticipated upcoming economic landscape. This decision comes after the country's largest bank surpassed analysts' predictions for the third ... Read More>>